241 related articles for article (PubMed ID: 9748133)
1. Circulating p53 antibodies as early markers of oral cancer: correlation with p53 alterations.
Ralhan R; Nath N; Agarwal S; Mathur M; Wasylyk B; Shukla NK
Clin Cancer Res; 1998 Sep; 4(9):2147-52. PubMed ID: 9748133
[TBL] [Abstract][Full Text] [Related]
2. Serum anti-p53 antibodies as a diagnostic tumor marker: observations in patients with malignant and premalignant oral cavity lesions.
Porrini R; Vercellino V; Rocchetti V; Renò F; Giorda E; Pomato E; Cannas M; Sabbatini M
Minerva Stomatol; 2010 May; 59(5):233-9, 239-43. PubMed ID: 20502428
[TBL] [Abstract][Full Text] [Related]
3. Anti-p53 and anti-heat shock proteins antibodies in patients with malignant or pre-malignant lesions of the oral cavity.
Castelli M; Cianfriglia F; Manieri A; Palma L; Pezzuto RW; Falasca G; Delpino A
Anticancer Res; 2001; 21(1B):753-8. PubMed ID: 11299839
[TBL] [Abstract][Full Text] [Related]
4. p53 expression above the basal cell layer in oral mucosa is an early event of malignant transformation and has predictive value for developing oral squamous cell carcinoma.
Cruz IB; Snijders PJ; Meijer CJ; Braakhuis BJ; Snow GB; Walboomers JM; van der Waal I
J Pathol; 1998 Apr; 184(4):360-8. PubMed ID: 9664901
[TBL] [Abstract][Full Text] [Related]
5. Serum p53 antibody is a useful tumor marker in superficial esophageal squamous cell carcinoma.
Shimada H; Takeda A; Arima M; Okazumi S; Matsubara H; Nabeya Y; Funami Y; Hayashi H; Gunji Y; Suzuki T; Kobayashi S; Ochiai T
Cancer; 2000 Oct; 89(8):1677-83. PubMed ID: 11042560
[TBL] [Abstract][Full Text] [Related]
6. Detection of survivin and p53 in human oral cancer: correlation with clinicopathologic findings.
Khan Z; Tiwari RP; Mulherkar R; Sah NK; Prasad GB; Shrivastava BR; Bisen PS
Head Neck; 2009 Aug; 31(8):1039-48. PubMed ID: 19340865
[TBL] [Abstract][Full Text] [Related]
7. The detection of quantitative serum p53 protein in lung cancer.
Sen E; Gönüllü U; Akar N
Tuberk Toraks; 2005; 53(3):231-7. PubMed ID: 16258881
[TBL] [Abstract][Full Text] [Related]
8. Prognostic significance of three hepatitis markers (p53 antibodies, vascular endothelial growth factors and alpha fetoprotein) in patients with hepatocellular carcinoma.
Gadelhak NA; Gadelhak SA; El-Morsi DA; Abdelaziz MM; Abbas AT; El-Emshaty HM
Hepatogastroenterology; 2009; 56(94-95):1417-24. PubMed ID: 19950803
[TBL] [Abstract][Full Text] [Related]
9. Serum p53 antibodies in patients with oral lesions: correlation with p53/HSP70 complexes.
Kaur J; Srivastava A; Ralhan R
Int J Cancer; 1997 Dec; 74(6):609-13. PubMed ID: 9421357
[TBL] [Abstract][Full Text] [Related]
10. Anti-p53 antibodies in sera from patients with chronic obstructive pulmonary disease can predate a diagnosis of cancer.
Trivers GE; De Benedetti VM; Cawley HL; Caron G; Harrington AM; Bennett WP; Jett JR; Colby TV; Tazelaar H; Pairolero P; Miller RD; Harris CC
Clin Cancer Res; 1996 Oct; 2(10):1767-75. PubMed ID: 9816128
[TBL] [Abstract][Full Text] [Related]
11. Presence of serum anti-p53 antibodies is associated with pleural effusion and poor prognosis in lung cancer patients.
Lai CL; Tsai CM; Tsai TT; Kuo BI; Chang KT; Fu HT; Perng RP; Chen JY
Clin Cancer Res; 1998 Dec; 4(12):3025-30. PubMed ID: 9865916
[TBL] [Abstract][Full Text] [Related]
12. p53 aberrations in oral sub mucous fibrosis and oral cancer detected by immunohistochemistry.
Bathi RJ; Prabhat
Indian J Dent Res; 2003; 14(4):214-9. PubMed ID: 15328987
[TBL] [Abstract][Full Text] [Related]
13. [Prognostic value of antibodies against p53 in patients with oral squamous cell carcinoma--five years survival rate].
Hofele C; Schwager-Schmitt M; Volkmann M
Laryngorhinootologie; 2002 May; 81(5):342-5. PubMed ID: 12001023
[TBL] [Abstract][Full Text] [Related]
14. Autoantibodies against P53 protein in patients with transitional cell carcinoma of the bladder.
Sanchez-Carbayo M; Chulia MT; Niveiro M; Aranda I; Mira A; Soria F
Anticancer Res; 1999; 19(4C):3531-7. PubMed ID: 10629648
[TBL] [Abstract][Full Text] [Related]
15. [The role of p53 tumor suppressor gene as prognostic factor in laryngeal squamous cell carcinoma].
Garozzo A; Cutrona D; Palmeri S; Maiolino L; Puzzo L; Allegra E
Acta Otorhinolaryngol Ital; 1999 Dec; 19(6):342-7. PubMed ID: 10875157
[TBL] [Abstract][Full Text] [Related]
16. Expression of p53 in oral squamous cell carcinoma is associated with the presence of IgG and IgA p53 autoantibodies in sera and saliva of the patients.
Warnakulasuriya S; Soussi T; Maher R; Johnson N; Tavassoli M
J Pathol; 2000 Sep; 192(1):52-7. PubMed ID: 10951400
[TBL] [Abstract][Full Text] [Related]
17. p53 inactivation in chewing tobacco-induced oral cancers and leukoplakias from India.
Saranath D; Tandle AT; Teni TR; Dedhia PM; Borges AM; Parikh D; Sanghavi V; Mehta AR
Oral Oncol; 1999 May; 35(3):242-50. PubMed ID: 10621843
[TBL] [Abstract][Full Text] [Related]
18. The presence of serum anti-p53 antibodies from patients with invasive ductal carcinoma of breast: correlation to other clinical and biological parameters.
Gao RJ; Bao HZ; Yang Q; Cong Q; Song JN; Wang L
Breast Cancer Res Treat; 2005 Sep; 93(2):111-5. PubMed ID: 16187230
[TBL] [Abstract][Full Text] [Related]
19. Overexpression of p53 protein in betel- and tobacco-related human oral dysplasia and squamous-cell carcinoma in India.
Kaur J; Srivastava A; Ralhan R
Int J Cancer; 1994 Aug; 58(3):340-5. PubMed ID: 8050814
[TBL] [Abstract][Full Text] [Related]
20. Titration of serum p53 antibodies in 1,085 patients with various types of malignant tumors: a multiinstitutional analysis by the Japan p53 Antibody Research Group.
Shimada H; Ochiai T; Nomura F;
Cancer; 2003 Feb; 97(3):682-9. PubMed ID: 12548611
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]